Skip to main content

Table 1 Characteristics of included studies

From: The prognostic significance of anti-angiogenesis therapy in ovarian cancer: a meta-analysis

First author Agents Journal Phase Year Treatment setting No. of patients Median follow-up time (months) FIGO stage Hazard ratio (95 % CI)
Control group Anti-angiogenic group Control group Anti-angiogenic group PFS OS
Pujade-Lauraine E [8] Bevacizumab JCO III 2014 Recurrent 182 179 13.9 13 0.48 (0.38–0.60) 0.85 (0.66–1.08)
Aghajanian C [9] Bevacizumab JCO III 2012 Recurrent 242 242 24 24 0.48 (0.39–0.61) 1.03 (0.79–1.33)
Perren TJ [10] Bevacizumab NEJM III 2011 Primary 764 764 19.4 19.4 I-IV 0.87 (0.77–0.99) 0.85 (0.69–1.04)
Burger RA [11] Bevacizumab NEJM III 2011 Primary 625 623 17.4 17.4 III-IV 0.64 (0.55–0.76) 0.92 (0.73–1.15)
Monk BJ [12] Trebananib Lancet Oncology III 2014 Recurrent 458 461 10.1 10.1 0.66 (0.57–0.77) 0.86 (0.69–1.08)
Karlan BY [13]a Trebananib JCO II 2012 Recurrent 55 53 14.9 15.4 I-IV 0.81 (0.51–1.30) 0.60 (0.34–1.06)
Karlan BY [13]b Trebananib JCO II 2012 Recurrent 55 53 14.9 15.2 I-IV 0.75 (0.49–1.21) 0.77 (0.45–1.31)
du Bois A [14] Pazopanib JCO III 2014 Primary 468 472 24 24 II-IV 0.77 (0.64–0.91) 1.08 (0.87–1.33)
Liu JF [15] Cediranib Lancet Oncology II 2014 Recurrent 46 44 16.6 16.6 0.42 (0.23–0.76)
Ledermann JA [16] Cediranib 2013 ESMO meeting III 2013 Recurrent 0.57 (0.45–0.74) 0.70 (0.51–0.99)
Ledermann JA [17] Nintedanib JCO II 2011 Recurrent 40 43 I-IV 0.65 (0.41–1.02) 0.84 (0.51–1.39)
du Bois A [18] Nintedanib 2013 ESGO meeting III 2013 Primary 455 911 IIB-IV 0.84 (0.72–0.98)
Gotlieb WH [19] Aflibercept Lancet Oncology II 2012 Recurrent 26 29 1.01 (0.56–1.86)
  1. aTrebananib:10mg/kg; b Trebananib:3mg/kg